Impact Factor
4.19
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.07
3,844 total citations
h5-index
78
h5 depth signal
Cited share
61.1%
410 of 671
Total citations
3,844
Citation footprint
Metric signal
5.82
External metric anchor
Self-citation
2.9%
112 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,820
United Kingdom
507
China
413
Canada
337
France
314
Citing Fields of Research
Musculoskeletal Disorders
2,150
Auto-Inflammatory Disorders
1,156
Immunology
812
Hematology
155
Genetics & Genomics
103
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,398
Articles tracked across the journal lifetime
Indexed publication set
671
410 cited publications
Last 12 months
448
37.3 publications/month
Open access share
42.0%
188 OA publications in the last year
Leading citing country
United States
1,820 citing publications
Leading citing field
Musculoskeletal Disorders
2,150 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v66n1, Jan, 2014-
v66n1, Jan, 2014-
Active Coverage
Research Focus & Classification
Indexed Subjects
Musculoskeletal Disorders
Auto-Inflammatory Disorders
Issuing & Sponsoring Bodies
issuing body
American College of Rheumatology
Broad Categories
Rheumatology
Musculoskeletal Disorders
MeSH Descriptors
Arthritis
Rheumatic Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/art.70359
Open DOI
Mesenchymal Stromal Cells Fuel Immunometabolic Reprogramming of Type 2 Conventional Dendritic Cells to Alleviate Systemic Sclerosis
Objective: This study aimed to investigate the clinical efficacy and underlying mechanisms of mesenchymal stromal cell (MSC) therapy in systemic sclerosis (SSc). Methods: We prospectively evaluated the efficacy of MSC therapy in patients...
02
DOI 10.1002/art.70356
Open DOI
Neutrophil‐Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis
Objective: Chronic recurrent multifocal osteomyelitis (CRMO) is a pediatric autoinflammatory bone disease with poorly defined pathophysiology and limited biomarkers. Murine models implicate neutrophils, neutrophil‐derived interleukin‐1β,...
03
DOI 10.1002/art.70353
Open DOI
Plasma Proteomics Identifies Molecular Signatures and Biomarkers Associated With High Structural Damage in Ankylosing Spondylitis
Objective: Pathologic bone formation in ankylosing spondylitis (AS) is not fully reflected by systemic inflammation, limiting the utility of markers of inflammation for structural damage assessment. This study aimed to identify plasma pr...
04
DOI 10.1002/art.70335
Open DOI
Expert Perspectives: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies
Treat‐to‐target has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment ...
05
DOI 10.1002/art.70372
Open DOI
Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis
Objective: Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods: We analysed...
06
DOI 10.1002/art.70361
Open DOI
Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.
Background: Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods: We conducted a retrospective cohort study using data from the National Clinical C...
07
08
DOI 10.1002/art.70360
Open DOI
Oral Glucocorticoid Dose Patterns and Organ Damage in Systemic Lupus Erythematosus—A Nationwide Cohort Study
Objective: Evaluating the relationship between glucocorticoid (GC) exposure and organ damage in systemic lupus erythematosus (SLE) is challenging because GC dose varies over time. It is unclear which exposure time window captures the ful...
09
DOI 10.1002/art.70345
Open DOI
Exploring the Potential of Cluster Analysis in Identifying Disease Phenotypes in Calcium Pyrophosphate Deposition: Moving From Intuition to Insight
Objective: Calcium pyrophosphate deposition (CPPD) disease is a heterogeneous condition and is frequently misdiagnosed due to the different clinical presentations and variable disease progression. Aim of this study is to identify clinica...
10
DOI 10.1002/art.70363
Open DOI
Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial
Objective: Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluat...
Bibliographical & Catalog Notes
Also issued online.